Clinical and Translational Oncology

, Volume 10, Issue 8, pp 517–521 | Cite as

Metastatic disease from chordoma

  • Gloria VergaraEmail author
  • Belén Belinchón
  • Francisco Valcárcel
  • María Veiras
  • Irma Zapata
  • Alejandro de la Torre
Case Reports


Chordomas are tumors with a bad prognosis, because of their location, local aggressiveness and high rate of local relapse. Despite of be benign tumors, they have certain capacity of metastasize and a clinical evolution that results interesting. When we analyzed our series with 35 chordomas studied and treated between 1975 and 2002, we found three patients that experienced a systemic dissemination.


Chordoma Metastases Radiotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sundaresan N, Boriani S, Rothman A, Holtzman R (2004) Tumors of the osseous spine. J Neurooncology 69:273–290CrossRefGoogle Scholar
  2. 2.
    Markwalder TM, Regula V, Markwalder RV et al (1979) Metastatic chordoma. Surg Neurol 12: 473–478PubMedGoogle Scholar
  3. 3.
    Soo MY (2001) Chordoma: review of clinicoradiological features and factors affecting survival. Australas Radiol 45:427–434PubMedCrossRefGoogle Scholar
  4. 4.
    Chetty RC, Levin VC, Kalan MR (1991) Chordoma: a 20-year clinicopathologic review of the experience at Groote Schuur Hospital, Cape Town. J Surg Oncol 46:261–264PubMedCrossRefGoogle Scholar
  5. 5.
    Fourney DR, Gokasian ZL (2003) Current management of sacral chordoma. Neurosurg Focus 15(2):E9PubMedCrossRefGoogle Scholar
  6. 6.
    McPherson CM, Suki D, McCutcheon IE et al (2006). Metastatic disease from spinal chordoma: a 10-year experience. J Neurosurg Spine 5:277–280PubMedCrossRefGoogle Scholar
  7. 7.
    McMaster ML, Goldstein AM, Bromley CM et al (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 12(1):1–11PubMedCrossRefGoogle Scholar
  8. 8.
    Tai PT, Craighead P, Liem SK et al (2000) Management issues in chordoma: a case series. Clin On col (R Coll Radiol) 12(2):80–86Google Scholar
  9. 9.
    St. Martin M, Levine SC (2003) Chordomas of the skull base: manifestations and management. Curr Opin Otolaryngol Head Neck Surg 11:324–327PubMedCrossRefGoogle Scholar
  10. 10.
    Romero J, Cárdenes H, De la Torre A et al (1993) Chordoma: results of radiation therapy in eighteen patients. Radiother Oncol 29:27–32PubMedCrossRefGoogle Scholar
  11. 11.
    Catton C, O’sullivan B, Bell R et al (1996) Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 41:67–72PubMedGoogle Scholar
  12. 12.
    Igaki H, Tokuuye K, Okumura T et al (2004) Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 60(4):1120–1126PubMedGoogle Scholar
  13. 13.
    Mendenhall WM, Mendenhall CM, Lewis SB et al (2005) Skull base chordoma. Head Neck 27(2):159–165PubMedCrossRefGoogle Scholar
  14. 14.
    Imai R, Kamada T, Tsuji H et al (2004) Carbon ion radiotherapy for unresectable sacral chordoma. Clin Cancer Res 10:5741–5746PubMedCrossRefGoogle Scholar
  15. 15.
    Casali PG, Stacchiotti S, Sangalli C et al (2007) Curr Opin Oncol 19:367–370PubMedCrossRefGoogle Scholar
  16. 16.
    Jacob HE (1994) Chemotherapy for cranial base tumors. J Neurooncol 20:327–335PubMedCrossRefGoogle Scholar
  17. 17.
    Schonegger K, Gelpi E, Prayer D et al (2005) Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs 16(10):1139–1143PubMedCrossRefGoogle Scholar
  18. 18.
    Fleming GF, Heiman PS, Stephens JK et al (1993) Dedifferentiated chordoma: response to aggressive chemotherapy in two cases. Cancer 72:714–718PubMedCrossRefGoogle Scholar
  19. 19.
    Auger M, Raney B, Callender D et al (1994) Metastatic intracranial chordoma in a child with massive pulmonary tumor emboli. Fetal Pediatr Pathol 14:763–770CrossRefGoogle Scholar
  20. 20.
    Casali PG, Messina A, Stracchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101: 2086–2097PubMedCrossRefGoogle Scholar
  21. 21.
    Hof H, Welzel T, Debus J (2006) Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29:572–574PubMedCrossRefGoogle Scholar
  22. 22.
    Clinical Trial Phase II. Efficacy and Safety of Imatinib in Chordoma, Milano, Italy. Novartis. NCT00150072/CSTI571BIT15Google Scholar
  23. 23.
    Bergh P, Kindblom LG, Gutenberg B et al (2000) Prognostic factors in chordoma of the sacrum and mobile spine (39 patients). Cancer 88(9):2122–2134PubMedCrossRefGoogle Scholar
  24. 24.
    Chambers PW, Schwinn CP (1979) Chordoma. A clinicopathologic study of metastasis. Am J Clin Pa thol 72(5):765–776Google Scholar
  25. 25.
    St. Delank KS, Kriegsmann J, Drees PH et al (2002) Metastasising chordoma of the lumbar spine. Eur Spine J 11(2):167–171CrossRefGoogle Scholar
  26. 26.
    Higinbotham NL, Phillips RF, Farr HW, Husyu HO (1967) Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 20:1841–1850PubMedCrossRefGoogle Scholar
  27. 27.
    Heffelfinger M J, Dahlin DC, MacCarty CS, Beabout JW (1973) Chordomas and cartilaginous tumors at the skull base. Cancer 32:410–420PubMedCrossRefGoogle Scholar
  28. 28.
    Asano S, Kawahara N, Kirino T (2003) Case report. Intradural spinal seeding of a clival chordoma. Acta Neurochir 145:599–603CrossRefGoogle Scholar
  29. 29.
    Baratti D, Gronchi A, Pennachioli E et al (2003) Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Onco 10:291–296CrossRefGoogle Scholar

Copyright information

© Feseo 2008

Authors and Affiliations

  • Gloria Vergara
    • 1
    Email author
  • Belén Belinchón
    • 1
  • Francisco Valcárcel
    • 1
  • María Veiras
    • 1
  • Irma Zapata
    • 1
  • Alejandro de la Torre
    • 1
  1. 1.Servicio de Oncología RadioterápicaHospital Puerta de HierroMadridSpain

Personalised recommendations